Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.13 - $2.88 $253,232 - $645,408
224,100 Added 125.61%
402,504 $1.16 Billion
Q4 2023

Feb 14, 2024

BUY
$1.21 - $1.44 $215,868 - $256,901
178,404 New
178,404 $228 Million

Others Institutions Holding RGLS

About Regulus Therapeutics Inc.


  • Ticker RGLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,634,400
  • Market Cap $22.5M
  • Description
  • Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...
More about RGLS
Track This Portfolio

Track Exome Asset Management LLC Portfolio

Follow Exome Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exome Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exome Asset Management LLC with notifications on news.